Evidence map›Paper›PMID 34013440›Full record

ReviewPharmacoEconomics2021

Overview and Use of Tools for Selecting Modelling Techniques in Health Economic Studies.

Huajie Jin, Stewart Robinson, Wenru Shang, Evanthia Achilla, David Aceituno, Sarah Byford

Abstract readReview
PubMed Publisher
In one paragraph

Review in PharmacoEconomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Huajie JinKing's Health Economics, Institute of Psychiatry, Psychology and Neuroscience at King's College London, The David Goldberg Centre, Box 024, London, SE5 8AF, UK. huajie.jin@kcl.ac.uk.ORCID http://orcid.org/0000-0002-3872-3998
Stewart RobinsonSchool of Business and Economics, Loughborough University, Epinal Way, Loughborough, LE11 3TU, UK.ORCID http://orcid.org/0000-0002-6016-0167
Wenru ShangSchool of Public Health, Fudan University, No. 130, Dongan Road, Shanghai, 200032, People's Republic of China.ORCID http://orcid.org/0000-0002-8779-5373
Evanthia AchillaIQVIA, 79 Anson Road, #19-01, Singapore, 079906, Singapore.ORCID http://orcid.org/0000-0002-7402-2769
David AceitunoKing's Health Economics, Institute of Psychiatry, Psychology and Neuroscience at King's College London, The David Goldberg Centre, Box 024, London, SE5 8AF, UK.ORCID http://orcid.org/0000-0002-2967-5816
Sarah ByfordKing's Health Economics, Institute of Psychiatry, Psychology and Neuroscience at King's College London, The David Goldberg Centre, Box 024, London, SE5 8AF, UK.ORCID http://orcid.org/0000-0001-7084-1495

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The availability and use of tools to guide the choice of modelling technique are not well understood. Our study aims to review existing tools and explore the use of those tools in health economic models. Two reviews and one case study were conducted. Review 1 aimed to identify tools based on expert opinion and citation searching and explore the value of the tools for health economic models. Review 2, based on citation searching, aimed to describe how those tools have been used in health economic models. Both reviews were conducted using Web of Science and Scopus. Two independent reviewers selected studies for inclusion. A case study, focused on economic evaluations of antipsychotic medication in schizophrenia, was conducted to compare the modelling techniques used by existing models with modelling techniques recommended by identified tools. Seven tools were identified, of which the revised Brennan's toolkit, was assessed to be the most appropriate for health economic models. The seven tools were cited 126 times in publications reporting health economic models. Only 17 of these (13.5%) reported that they used the tool(s) to guide the choice of modelling technique. Application of these tools suggested discrete event simulation is most appropriate for modelling antipsychotic medication in schizophrenia, but discrete event simulation was only used by 17% of existing models. There is considerable inconsistency between the modelling techniques used by existing models and modelling techniques recommended by tools. It is recommended that for future modelling studies the choice of modelling technique should be justified, this can be achieved by the application of model selection tools, such as the revised Brennan's toolkit. Future research is required to explore the barriers to using model selection tools in health economic models and to update existing tools and make them easier to use.

Indexed as

Antipsychotic AgentsSchizophreniaCost-Benefit AnalysisEconomics, MedicalHumansModels, EconomicAntipsychotic Agents

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.